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Abstract: Atherosclerotic cardiovascular disease is the foremost cause of death and disability 
in the Western world, and it is rapidly becoming so in the developing nations. Even though the 
use of statin therapy aiming at the low-density lipoprotein cholesterol (LDL) has significantly 
reduced cardiovascular events and mortality, substantial residual cardiac events still occur in 
those being treated to the currently recommended targets. In fact, residual risk is also seen in 
those who are treated “aggressively” such as the “high risk” patients so defined by the National 
Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III). Consequently, one 
must look for the predictors of risk beyond LDL reduction. High-density lipoprotein cholesterol 
(HDL) is the next frontier. The protectiveness of elevated HDL against atherosclerosis is well 
described in the literature. HDL subdues several atherogenic processes, such as oxidation, 
inflammation, cell proliferation and thrombosis. It also helps mobilize the excess LDL via 
reverse cholesterol transport. Low levels of HDL have been shown to be independent predictors 
of risk. Thus, therapies to raise the HDL hold promise for additional cardiac risk reduction. In 
this regard, several randomized trials have recently tested this hypothesis, especially in patients 
at high risk. In addition to the use of aggressive lifestyle modification, clinical outcomes have 
been measured following augmentation of HDL levels with various treatment modalities, 
including aggressive statin therapy, combination therapy with fibrates and niacin, and direct 
HDL-raising drug treatments. These data for low HDL as an independent risk factor and as the 
new treatment target are reviewed in this paper.
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X-receptor agonists, PPAR-alpha agonists, Cordaptive™, D-4F agonists, farnesoid X-receptor 
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Introduction
Atherosclerotic heart disease continues to be the foremost cause of mortality in the 
United States for both men and women.1,2 It is well established that statins significantly 
reduce the number of recurrent cardiovascular events and have been the principal 
contributor for reduction in coronary heart diseases (CHD) death rates over the past 
2 decades. However, the management of dyslipidemia in both the primary and   secondary 
prevention settings has focused on low-density lipoprotein cholesterol (LDL) reduction 
as the primary target. Nonetheless, a worrisome number of residual events still occur 
in patients who are on adequate statin treatment as seen in several of the major ran-
domized trials. For example, the Pravastatin or Atorvastatin Evaluation and Infection 
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to New Targets (TNT), and the Incremental Decrease in End 
Points Through Aggressive Lipid Lowering (IDEAL) trials 
have now demonstrated that even when LDL was adequately 
lowered with statin therapy, a   substantial number of residual 
cardiovascular events continued to occur.3–5 A treatment strat-
egy solely targeting the LDL with statins, therefore, may not 
be the best lipid treatment strategy for CHD management. 
Therapeutic lipid treatment strategies that involve additional 
targets beyond mere LDL reduction must be explored.
High-density lipoprotein cholesterol (HDL) is one such 
lipid molecule that bears an inverse relationship with CHD 
and incidence of recurrent cardiovascular events. It has a 
cardio-protective effect, and higher levels of HDL may impart 
longevity. Data from the Framingham Heart Study have 
shown that subjects with the highest HDL levels exhibit the 
lowest risk of developing CHD. Prospective, observational 
studies conducted throughout the world have consistently 
demonstrated that high serum levels of HDL are associated 
with reduced risk for CHD development and related com-
plications such as myocardial infarction (MI), stroke, and 
death, whereas low serum levels of this lipoprotein are cor-
related with increased risk for cardiovascular morbidity and 
mortality in both men and women. Low serum levels of HDL 
also portend increased risk for cardiovascular morbidity and 
mortality in patients treated with drug-eluting stents.
HDL and its sub-fractions are able to provide cardiac 
protection through various anti-atherogenic actions, such as 
their effectiveness against inflammation, oxidation, throm-
bosis, and cell proliferation. Among lipoproteins, HDL is 
also unique, in that, unlike atherogenic lipoproteins, which 
infiltrate arterial walls and deposit cholesterol and lipid 
within resident macrophages in the subendothelial space, 
HDL promotes the mobilization and clearance of excess lipid 
away from the arteries in a series of reactions collectively 
termed the reverse cholesterol transport. Numerous thera-
peutic agents are being developed in an attempt to modulate 
serum levels of HDL as well as its functions. Thus, a new 
therapeutic strategy seems to be taking shape. HDL is fast 
becoming the next major target to be tackled in the field 
of lipidology, in which raising the level of HDL is being 
considered highly desirable. In recent years both basic science 
and clinical research studies have provided data suggesting 
that therapies that raise HDL may augment risk reduction in 
patients with CHD.
This review will focus on the trials and tribulations of the 
mechanisms, magnitude of risk, and the methods of raising 
HDL for further reduction of cardiovascular risk beyond LDL 
by raising HDL levels or modifying its properties.
Low HDL 
(hypoalphalipoproteinemia)
Low levels of HDL, also known as hypoalphalipoproteinemia 
(HA), includes a variety of conditions, ranging from mild to 
severe, in which plasma concentrations of alpha lipoproteins 
or HDL are below the NCEP cutoff for desirable HDL level 
described above. The etiology of HDL deficiency range from 
secondary causes, such as smoking, to primary or familial 
causes including specific genetic mutations, such as Tangier 
disease and fish-eye disease. Hypoalphalipoproteinemia has 
no clear-cut definition. An arbitrary cutoff used frequently in 
the old literature includes a HDL level that falls within the 
10th percentile of HDL levels.
A more practical definition derives from the theoretical 
cardioprotective role of HDL. The US National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III 
(ATP III) redefined the HDL level that constitutes a formal 
CHD risk factor. The minimum desirable level was raised 
from 35 to 40 mg/dL for both men and women. For persons 
with metabolic syndrome, however, the designated HDL 
levels that contribute to the syndrome are gender-specific. For 
men, a desirable HDL level is still one that is above 40 mg/dL, 
but for women, the desirable level is greater than 50 mg/dL 
to satisfy the definition of metabolic syndrome.
HDL: an independent CHD risk factor
In the latest report, the NCEP ATP-III guidelines clearly indi-
cate that low HDL is a significant and independent risk factor 
for CHD.6 The relationship is inversely proportional, such that 
1 mg/dL rise in HDL imparts 2% to 3% reduction in CHD 
risk.7 Low HDL is frequently associated with high triglycer-
ides and remnant lipoprotein levels. Furthermore, low HDL 
is quite prevalent in the US according to the third National 
Health and Nutrition Examination Survey (NHANES III). 
Approximately 35% of adult men have HDL,40 mg/dL and 
39% of women have HDL,50 mg/dL.8 Analysis of data from 
the Framingham study revealed that there was a significant 
increase in CHD events in patients who had low HDL at all 
levels of LDL.9 Furthermore, it has been described that the 
patient with desirable LDL level (100 mg/dL) in association 
with low HDL (25 mg/dL) level would have a CHD risk 
equivalent to a patient with elevated LDL (220 mg/dL) but 
a higher, desirable HDL level (45 mg/dL).9 Thus, it has now 
become quite apparent that low concentration of HDL is a 
significant and independent risk predictor for CHD.
A prospective meta-analysis of 14 randomized trials 
was performed by the Cholesterol Treatment Trialists’ 
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with adult-onset (type 2) diabetes. After a mean   follow-up of 
5 years, with 8,186 deaths and 14,348 major cardiovascular 
events, the statin-treated patients with low HDL (#35 mg/dL) 
showed a significantly higher rate of major cardiovascular 
events than those with higher HDL levels (.42.5 mg/dL).10 
Thus, statin treatment alone does not appear to be good 
enough to eliminate the risk associated with low HDL. This 
analysis, again, suggests that a focus exclusively on LDL 
reduction falls short of best possible CHD risk reduction.
The European Prospective Investigation into Cancer and 
nutrition – Norfolk cohort (EPIC-Norfolk) and the Incre-
mental Decrease in End Points through Aggressive Lipid 
Lowering (IDEAL) trials examined the relationship between 
plasma HDL level, HDL particle size, level of apolipoprotein 
(apo A-1), and their relationship with CHD events.11 In both 
trials, HDL was found to have a significant protective effect 
on recurrent CHD events. For apo A-1 and apo B, there 
was a protective/inverse relationship with risk for a major 
CHD event when HDL was over 70 mg/dL in the IDEAL 
study. The apo A-1 remained strongly inversely associated 
with CHD events in IDEAL, and HDL particle size and 
apo B in EPIC-Norfolk at any level of HDL. Similarly, the 
Treating to New Targets (TNT) study (subgroup analysis 
of 2661   subjects) showed that patients in the aggressively 
treated group who had achieved the lowest LDL levels of 
about 58 mg/dL still exhibited a significant risk of major 
cardiovascular events over the 5 year follow up if their 
HDL-C was low.12 The subjects in the highest HDL quintile 
(HDL $ 55 mg/dL) showed significantly lower major CHD 
events than those in the lowest quintile (HDL , 37 mg/dL, 
P = 0.03; Q5 hazard ratio [HR] = 0.61).11 Thus, even the 
most aggressive statin therapy to achieve very low levels of 
LDL does not eliminate the risk of CVD events when the 
HDL-C is low.
HDL: production, pathophysiology  
and metabolism
Lipid molecules, such as HDL and LDL, circulate in the 
plasma complex with proteins termed lipoproteins, which act 
as carriers. Such complexed plasma lipoproteins are macro-
molecular structures that are classified based on their physi-
cal properties, ie, density and electrophoretic mobility. The 
overall structure of all lipoproteins is similar. The nonpolar 
lipid molecules, ie, cholesteryl ester, and triglycerides (TGs), 
circulate in a core surrounded by more polar components, 
eg, free cholesterol, phospholipids, and proteins. The protein 
components, appropriately termed apolipoproteins, play a key 
role in lipoprotein metabolism. The major   apolipoproteins of 
HDL are alpha lipoproteins (ie, apolipoprotein A-1 apo A-1, 
apo A-2, and apo A-4). Alpha lipoproteins are soluble and 
can move between different classes of lipoproteins relatively 
freely. In contrast, the beta lipoproteins, also called apoli-
poprotein B (apo B), do not move as freely, and are mostly 
associated with lower-density lipoproteins. For example, 
apo B-100 constitutes LDL, very low-density lipoproteins 
(VLDL), VLDL remnants, and intermediate-density lipopro-
teins (IDL), while apo B-450 is associated with chylomicrons 
and the remnants.
HDL plays an important role in reverse cholesterol 
transport (RCT), extracting cholesterol from the peripheral 
tissues and routing it to the liver. In the general population, 
lower-than-normal HDL-C levels are inversely correlated 
with CHD; the risk of a coronary event is thought to increase 
2% for every 1% decrease in HDL. However, extreme HDL 
deficiencies caused by rare autosomal recessive disorders, 
including familial HA, familial lecithin-cholesterol acetyl-
transferase (LCAT) deficiency, and Tangier disease, do not 
always correlate with more frequent CHD.
Apo A-1 is the major HDL protein, constituting approxi-
mately 70% of the apolipoprotein content of the HDL mol-
ecule.13 Apo A-1 is produced in the liver and intestine and is 
initially secreted as a lipid-void apo A-1 molecule, sometimes 
termed as pre-HDL particle, and the lipid   component is sub-
sequently added to it in the presence of transport proteins. 
One such cellular lipid transport protein, the   adenosine tri-
phosphate (ATP)-binding cassette transporter A-1 (ABCA-1), 
is required for normal lipidation of lipid-void apo A-I 
lipoprotein. During this process of lipidation phospholip-
ids and unesterified cholesterol elements are effluxed and 
added to the lipid-void apoA-1 molecules. When ABCA-1 
is absent or dysfunctional, the apo A-1 gets catabolized too 
quickly leading to lower levels of apo A-1, and thus lower 
levels of HDL. Interestingly, the ABCA-1 transporter protein 
is expressed in almost all tissues; however, only liver and 
intestine are the primary sites where lipidation of lipid-void 
apo A-1 takes place.
Components of plasma HDL
Plasma HDL is a small, dense, spherical lipid-protein 
  structure, with the lipid and protein components each consti-
tuting half of the molecule. Major lipid constituents include 
phospholipid, cholesterol, cholesteryl esters, and triglycer-
ides, while the main proteins constituents include apo A-1 
(molecular weight, 28,000 Da) and apo A-2 (molecular 
weight, 17,000 Da). Other minor proteins found in smaller 
amounts include apo C-1, apo C-2, apo C-3, and apo-E. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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HDL molecules vary in molecular content and are relatively 
heterogeneous. Based on size and density, the HDL can be 
classified into larger, less dense HDL-2 and smaller, denser 
HDL-3 particles. The majority of the HDL exists as HDL-3. 
However, individual variability in HDL levels is usually due 
to variability in the quantity of HDL-2 particles.
Properties of HDL
Antiatherogenesis: RCT
RCT is considered to be the principal mechanism through 
which HDL exerts its cardioprotective effect. Macrophages 
present in the arterial wall are primarily involved in this pro-
cess. Acting as cellular scavengers, the macrophages absorb 
products of wear and tear, such as dead cells, modified lipo-
proteins, and extracellular debris. A large volume of choles-
terol is phagocytosed in this process, too. Cholesterol, in its 
unesterified form, is toxic to macrophages and can ultimately 
lead to apoptosis. Such apoptosis, however, is avoided, and 
atherosclerosis begins to take a foothold in the presence 
of an esterifying enzyme, acyl-coenzyme-A cholesterol 
O-acyltransferase-1 (ACAT-1). The process of atherosclerosis 
begins as follows. First, the ACAT-1 esterifies the cholesterol 
molecule making it hydrophobic, which, in turn, avoids going 
through cell death or apoptosis and begins to accumulate as 
lipid droplets within the cytoplasm. Cells loaded with such 
lipid droplets are called foam cells. The HDL molecule gets 
involved at this very step to prevent the formation of foam 
cells (anti-atherogenic effect). It intercepts the cholesterol 
molecules that efflux from the macrophages and undergoes 
lipidation. Several macrophage receptors are required for 
actively effluxing the cholesterol from the macrophages 
before lipidation of HDL. These receptors include ATP-
binding cassette transporter A-1 (ABCA-1), ATP-binding 
cassette transporter G-1 (ABCG-1), and scavenger receptor 
class-B type-1 (SR-B1. The ABCA-1 receptor molecule is 
responsible for lipidating only newly secreted apoA-1, while 
the ABCG-1 and SR-B1 receptors can directly lipidate HDL 
molecule. The ABCA-1 and ABCG-1 receptors are regulated 
by the nuclear liver-X-receptors-alpha   (LXR-alpha) and 
LXR-beta.
Thus, the first step of RCT involves efflux of choles-
terol from the macrophages before it could get esterified by 
ACAT-1 within the macrophage. The efflux occurs under 
the influence of LXR-alpa and LXR-beta that regulates the 
macrophage receptors ABCA-1, ABCG-1 and SR B-1, and 
facilitate lipidation of apo A-1 and HDL. Once cholesterol 
gets associated with HDL, it becomes esterified through 
the action of another enzyme, LCAT.13 Cholesterol ester, 
thus produced, is, again, hydrophobic and it accumulates 
to the center of the lipoprotein molecule, producing mature 
HDL.14 Subsequently, the mature HDL is transported to 
the liver where it releases the cholesterol for excretion into 
the bile. Selective uptake of HDL by the liver is mediated 
by the hepatic receptor, scavenger receptor class B type 1 
(SR-B1). Once in the liver, the cholesterol is either converted 
to bile acids before excretion or gets excreted directly into 
the bile.
In the absence of LCAT, mature HDL particles fail to 
form, and, thus, the immature HDL molecules become dys-
functional, and remain incapable of carrying out the RCT 
process. Even heterozygous patients for LCAT gene have 
been shown to be unable to form mature HDL molecules, and 
exhibit evidence of progressive atherosclerosis as indicated 
by increased carotid intima-media thickness (CIMT).
There is an alternative pathway that utilizes cholesterol 
ester transfer protein (CETP). CETP mediates the transfer of 
esterified cholesterol from HDL to apo B-containing proteins 
(eg, apo B-100) in equal 1:1 exchange for TG. Increased 
CETP activity lowers HDL and may reduce the amount 
of cholesterol delivered back to the liver via direct RCT. 
As a result pro-atherogenic activity may become enhanced. 
  Suppression of CETP activity has recently been the focus of 
development of new therapeutic agents for raising plasma 
levels of HDL.15
Additional beneficial properties of HDL
Several other properties of HDL beyond its involvement 
in the RCT pathway exert additional anti-atherogenic 
influence.16,17 HDL has been shown to directly stimulate 
  tissue plasminogen activator (tPA) and inhibit the expres-
sion of plasminogen activator inhibitor-1 (PAI-1). It also 
decreases the expression of adhesion molecules, such as 
vascular cell adhesion molecule-1 (VCAM-1), intercellular 
adhesion molecule-1 (ICAM-1) and monocyte chemoattract 
protein-1 (MCP-1). This action is accomplished by suppres-
sion of sphingosine kinase causing reduced production sphin-
gosine-1-phosphate and subsequently, lowering the quantity 
of nuclear factor kappa-B (NK-kappa-B) which is required 
for adequate expression of the adhesion molecules.
In addition, HDL promotes vasodilation by enhanc-
ing the formation of prostacyclin by acting as a substrate 
(ie, arachidonic acid) which is acted upon by the enzyme, 
cyclooxygenase, present on the endothelial cells. HDL has 
been implicated in curtailing the apoptosis and promoting 
the proliferation and migration of endothelial cells especially 
when damaged through the inhibition of the activation of Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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  caspase-3 and caspase-9. Finally, HDL has been shown to 
directly enhance nitric oxide production by stabilizing mRNA 
transcripts for nitric oxide synthase in the vascular   endothelium. 
Vascular dilatation and myocardial perfusion both have been 
shown to vary in proportion to the HDL levels.
Because of the above properties, the propensity and risk 
for thrombosis are significantly reduced in the presence of 
higher levels of HDL. By increasing the endothelial produc-
tion of tPA, prostacyclin, and nitric oxide, HDL reduces the 
platelet reactivity and coagulability. It also decreases the 
production of thromboxane A2 in the platelets. Generation of 
thrombin is reduced as does the thrombin-dependent platelet 
aggregation. HDL also enhances protein-C and protein-S 
activation, and reduces formation of the tissue factor curtail-
ing the coagulability.
Variants, prevalence and causes  
of low HDL
Variant apolipoproteins
The variant apo A-I Milano appears to share HDL proper-
ties. Low levels of apo-A-1 Milano are associated with 
increased risk of atherosclerotic cardiovascular disease, and 
increasing its level has been shown to be protective. Other 
less well-known variants that include apo A-1 Marburg, apo 
A-1 Giessen, apo A-1 Munster, and apo A-1 Paris, cause 
hypoalphalipoproteinemia, but do not seem to increase the 
risk of atherosclerosis.
Prevalence of HA (low HDL)
Hypoalphalipoproteinemia is frequently found in patients 
with CHD. Research indicates that 58% of patients with CHD 
have HDL levels below the 10th percentile of normal values. 
On the other hand, according to the NHANES III survey report, 
approximately 35% of adult men have HDL,40 mg/dL and 
39% of women have HDL,50 mg/dL in the US. Prevalence 
of low HDL is higher in certain ethnic populations, such as 
those of South Asian Indian descent.
Causes of low HDL/HA
HA may be caused by familial or primary and secondary 
disorders that are associated with low plasma levels of HDL. 
A number of various primary (or familial) causes as well as 
secondary causes and associations are listed below:
Familial or primary causes
Decreased or absent synthesis of apo A-I due to a defect at 
the level of the genes is the cause of hypoalphalipoproteine-
mias characterized by apo A-1/apo C-3 and apo A-1/apo 
C-3/apo A-4 deficiency. However, the etiology of the low 
levels of HDL is unclear for most of the remaining familial 
HAs. Some of the other underlying causes include increased 
catabolism, decreased synthesis, and altered equilibration 
of HDL between intravascular and extravascular spaces. 
Whatever the cause, these disorders are associated with 
altered HDL composition as well as altered equilibration 
of cholesterol, among the various lipoprotein classes. Main 
familial alphalipoproteinemias include familial apo A-1 defi-
ciency and structural mutations, familial LCAT deficiency, 
Tangier disease, and several less defined familial conditions 
such as familial HDL deficiency, familial apo A-1 and apo 
C-3 deficiency (apo A-1 absence), familial deficiency of apo 
A-1 and apo C-3, fish-eye disease (partial LCAT deficiency), 
familial HA, and presence of Apo A-1 variants, eg, apo A-1 
Milano, apo A-1 Marburg, apo A-1 Giessen, and apo A-1 
Munster.17
Secondary causes
Secondary causes or conditions associated with hypo-
alphalipoproteinemia include obesity, metabolic syndrome, 
physical inactivity, type 2 diabetes, cigarette smoking, 
end-stage renal disease, hypertriglyceridemia, treatment 
with probucol, androgens or progestins, use of high-dose 
thiazide diuretics and high-dose beta blockers, very low-fat 
diet,   dysglobulinemia, severe liver disease, malabsorption, 
malnutrition, and severe inflammatory disease.17
Special populations: South Asian indians
Americans of South Asian descent, especially those from the 
Indian subcontinent, African Americans, and Hispanics 
  represent a special group of people that show a much greater 
prevalence of cardiovascular disease and coronary risk 
  factors as compared with white American counterparts. 
Persons who can claim their origin to the Asian and Pacific 
Islander population consist of two very diverse kinds of 
population with regards to their overall cardiovascular 
disease risk. South Asia is generally represented by India, 
Pakistan,   Bangladesh, Nepal, and Sri Lanka; and South-East 
and Far East Asia is represented by Singapore, Malaysia, 
Thailand, the Philippines, China, Hong Kong, and Japan. The 
South Asian Indian Americans form a high risk subset and 
exhibit a 2-fold higher cardiac mortality rate compared with 
  Caucasians, irrespective of their gender, religion, social class, 
or dietary practices.18 By contrast, persons of East Asian and 
Far East descent, such as those of Chinese and Japanese 
origin, experience a much lower burden of cardiovascular 
prevalence and concomitant mortality rates.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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The explanation for such a high prevalence of CHD and 
mortality rates in the South Asian Indians appears to be a 
combination of genetic predisposition and environmental 
interaction. Increased prevalence of low HDL has been 
found to be one such underlying factor. An analysis of the 
INTERHEART study highlights the high prevalence of low 
plasma levels of HDL in South Asian persons as compared 
with other Asian counterparts.19 In this study, over 80% of 
participants, both with and without the history of prior acute 
myocardial infarction (AMI), exhibited low levels of HDL, 
ie, less than 50 mg/dL in women and under 40 mg/dL in 
men. The INTERHEART study, conducted in 52 countries 
at about 262 study sites around the World, evaluated 15,152 
patients with their first occurrence of AMI and 14,820 
age- and gender-matched controls. Focusing on South 
Asians, roughly a third of the participants (5,731 cases of 
AMI and 6,459 controls) were subjected to a sub-analysis 
comparing lipid and lipoprotein levels for various Asian 
sub-populations and non-Asians. The prevalence of low 
HDL levels was much higher in the South Asian population 
(82% of AMI cases and 81% of controls) than in the other 
(60% of AMI cases and 50% of controls). Furthermore, 
while the presence of higher levels of HDL correlated 
with a decreased risk of AMI, the extent of decrease in 
risk seemed to be less prominent for South Asians than for 
other Asians (odds ratio for 1 SD elevation in HDL 0.87 in 
South Asians vs 0.77 in others. Thus, while a 1 SD increase 
in HDL was associated with a 23% reduction in AMI risk 
in other Asians, it caused a mere a 13% risk reduction in 
the South Asians. Increases in apo A-1, however, seemed 
to be equally   protective. The lower levels of HDL in South 
Asians observed in the INTERHEART study reinforce the 
relevance of interventions aimed at raising HDL in this 
population. The authors concluded: ‘The low level of HDL 
among South Asians requires further study and targeted 
intervention’.
A study reported by Dodani et al attempted to identify 
apo A-1 polymorphisms, the main protein component of 
HDL and explore its association with low HDL levels in 
South Asians.20 The study was conducted on 30 South Asians. 
DNA extraction, and sequencing of apo A-1 gene were per-
formed. DNA sequencing revealed 6 novel apo A-1 single 
nucleotide polymorphisms (SNPs) in South Asians, one of 
which (rs35293760, C938T) was significantly associated with 
low (, 40 mg/dL) HDL levels (P = 0.004). The association 
was also seen with total cholesterol (P = 0.026) and LDL 
levels (P = 0.032). This pilot work has highlighted some of 
the gene-environment associations that could be responsible 
for low HDL and, possibly the excess burden of CHD among 
South Asians.
Further larger studies are required to explore and further 
elucidate these associations which may, one day, lead to 
better targeted therapies.
Management of low HDL
The NCEP ATP III guidelines now recognize low HDL 
level as a categorical and independent risk factor for CHD. 
Low serum HDL level is also one of the defining features of 
metabolic syndrome. It is estimated that approximately 35% 
of men and 39% of women residing in the United States have 
low serum levels of HDL. This is an important and widely 
prevalent risk factor that must be addressed in the clinical 
contexts of primordial, primary, and secondary prevention.
Attempts to raise HDL are becoming increasingly 
frequent in the literature and most agree that raising HDL 
should be one of the goals in the management of atherogenic 
dyslipidemias for CHD risk reduction. While statin, niacin, 
and fibrate therapies have been demonstrated to increase HDL 
to a varying extent and improve cardiovascular outcomes, 
a number of newer therapeutic agents have now appeared 
on the horizon that hold promise for raising HDL. These 
agents include infusible HDL type agents, new peroxisome 
proliferator activated receptor-alpha (PPAR-alpha) agonists, 
liver-X receptor-alpha (LXR-α) agonists, CETP inhibitors, 
D-4F and other apo A agonists, Cordaptive™, and farnesoid 
X receptor (FXR) antagonists. Each of these novel therapies 
will be briefly reviewed in the following sections.
international and national guidelines and low HDL
American Heart Association (AHA)  
Guidelines for women
In light of the increasing prevalence of CHD in women, AHA 
highlighted the evidence based guidelines for CHD preven-
tion in women in its 2004 guidelines as well as its update 
in 2007.21,22 The AHA guidelines recommend lipid goals of 
LDL under 100 mg/dL, HDL to be above 50 mg/dL, triglyc-
erides ,150 mg/dL, and non-HDL ,130 mg/dL. Therapeutic 
  lifestyle changes were recommended as the main therapy. 
However, for women with persistent low HDL the AHA guide-
lines state that niacin or fibrate therapy should be initiated.22
NCeP ATP iii statement
The NCEP ATP III guidelines state that LDL is the primary tar-
get for lipid-lowering therapy. In their 2004 update,   however, 
they recognized that elevated triglyceride and low HDL levels 
contribute to CHD risk, even after LDL goals have been met. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Thus, combination therapy may be required in this regard. 
The 2004 update to the NCEP ATP III guidelines has the 
following additional recommendation: ‘For those high-risk 
patients who have elevated triglycerides or low HDL levels, 
addition of a fibrate or nicotinic acid to the routine LDL-
lowering therapy can be considered’.23
American Diabetes Association (ADA) guidelines
It is well known that the patients with type 2 diabetes have a 
2- to 4-fold higher risk for CHD. The most common form of 
dyslipidemia in the diabetics includes co-existence of high 
levels of TG and low serum levels of HDL.24 ADA 2008 
guidelines recommend initiation of statin therapy to lifestyle 
therapy irrespective of the lipid levels for all diabetics who 
have either manifest CHD or $1 other CHD risk factor and 
are over the age 40 in the absence of manifest CHD. For 
lower-risk diabetics, such as those without diagnosed CHD 
and those younger than 40 years, addition of statin should 
be considered if LDL continues to exceed 100 mg/dL.25 
In addition, the guidelines recommend attainment of TG 
levels below 150 mg/dL and HDL above 40 mg/dL in men 
and 50 mg/dL in women.
According to the guidelines, combination therapy with 
statin and an additional agent such as a fibrate or niacin may 
be efficacious for treatment of these mixed lipid abnormali-
ties (ie, high LDL, low HDL, and elevated TG). Despite the 
concern over niacin use and potential for the interference 
with glucose control, it has been shown that niacin in moder-
ate doses, ie, 750 to 2000 mg daily, significantly improves 
LDL, HDL, and TG levels and causes only minor variation 
in glucose level that can be generally corrected through 
therapeutic adjustment.
American College of Cardiology (ACC) and ADA: 
combined recommendations
ACC and ADA published a consensus statement in 2008 
that provides recommendations for patients with elevated 
global cardiometabolic risk (CMR). Patients with elevated 
CMR often present with mixed type of atherogenic dys-
lipidemia characterized by elevated TG, low HDL, and 
increased numbers of small, dense LDL particles.26 Other 
than dyslipidemia, such patients also tend to have central 
obesity, insulin resistance, and hypertension. The consen-
sus statement recommends LDL and non-HDL goals for 
patients with CMR and lipoprotein abnormalities based on 
their CHD risk. Statins are recommended as the first line 
of therapy; however, combination therapy is recommended 
for patients on statin therapy who also have low HDL or 
elevated non-HDL, especially if apo B levels are also high. 
According to the guidelines, niacin is the preferred agent for 
use in combination with statins because of the availability 
of greater evidence for CHD event reduction with niacin 
compared with fibrates.26
General management of low HDL
Diagnosis of HA
Most individuals are diagnosed with HA based on the 
results of a routine lipid profile measurement. This finding 
of a HDL-C level can be useful as an independent factor in 
assessing coronary artery disease (CAD) risk and further 
management. The Guidelines in the ATP III report empha-
sized the importance of HDL-C; the level of HDL was 
considered to be a significant risk factor, and the “desirable” 
level was changed from 35 mg/dL to 40 mg/dL for both men 
and women. Interestingly, to satisfy the definition of meta-
bolic syndrome, the cutoff risk level is stated to be 40 mg/
dL for men, but for women it is 50 mg/dL.
Principles and goals of HDL therapy
The basic purpose of the management of low HDL and related 
dyslipidemias is to reduce the risk of atherosclerosis and 
its sequelae. For HDL, the ATP III report states ‘Low HDL 
cholesterol is a strong independent predictor of CHD’. In the 
present guidelines, presence of low HDL-C level both modi-
fies the goal for LDL-lowering therapy and is used as a risk 
factor to estimate 10-year risk for CHD. While contemplating 
therapy, the ATP III recommends that the causes and associa-
tions of low HDL must be ascertained and treated to their 
target as the first step before considering specific therapy. 
These causes include type II diabetes, overweight status and 
obesity, elevated TGs, lack of physical activity, associated 
insulin resistance, cigarette smoking, very high carbohydrate 
intake (.60% of calories), and use of certain pharmacologic 
agents such as progestational drugs, and anabolic steroids.
Unlike the establishment of a target LDL level, The ATP 
III report does not provide a specific level which a low HDL 
concentration should be raised to. The panel stated that although 
clinical trial results suggest that raising HDL may reduce CHD 
risk, the evidence is yet insufficient to specify a target level of 
therapy. It is also influenced by the fact that currently available 
drugs do not robustly raise HDL. At the present juncture, the 
low HDL levels should be managed in the following manner: 
First,   reduction of LDL to defined   target levels remains as the 
primary goal. Metabolic syndrome is the second target after the 
LDL goal has been achieved. The emphasis should then shift 
to therapeutic lifestyle changes, such as weight reduction and Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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increased physical activity when the metabolic syndrome 
is present. Diagnosis of metabolic syndrome can be made 
in the presence of 3 or more of the following 5 risk factors: 
(a) abdominal obesity, with a waist circumference over 
40 inches (100 cm) (in men) or above 35 inches (88 cm) (in 
women); for South Asians the cutoff is 35 inches (88 cm) 
(for men) and 32 inches (80 cm) (for women) respectively, 
(b) TG level of 150 mg/dL or greater, (c) HDL level below 
40 mg/dL (males) or less than 50 mg/dL (females), (d) blood 
pressure at or above 130 mmHg systolic and greater than or 
equal to 85 mmHg diastolic, and (e) fasting glucose levels 
at or above 110 mg/dL.
The interaction between low HDL and hypertriglyc-
eridemia requires special attention because such mixed 
dyslipidemia is associated with aggressive atherogenecity. 
The ATP III reported that when a low HDL level is present 
in association with high levels of TG (200 to 499 mg/dL), 
secondary priority, right after achievement of LDL goals, 
must go to achieving the non-HDL goal. These target levels 
as defined by NCEP ATP-III are as follows:
(i)    In the patients with established CHD or a CHD risk 
equivalent (10-year risk for CHD .20%), the LDL 
goal is ,100 mg/dL, and the goal for non-HDL 
  choleseterol (LDL plus VLDL) is ,130 mg/dL;
(ii)    In persons with multiple (2+) risk factors and 10-year 
risk of equal to or less than 20%, the LDL goal is ,130 
mg/dL, while the non-HDL goal is ,160 mg/dL; and
(iii)  In persons with 0–1 risk factor, the LDL goal is 
,160 mg/dL, and that for the non-HDL is ,190 mg/dL.
Treatment of isolated low HDL
Treatment of isolated low HDL has gained increasing impor-
tance in the literature in the recent years. According to the 
ATP III, if a patient’s TG levels are below 200 mg/dL and 
the HDL is low (isolated low HDL), the administration of 
drugs that increase HDL (fibrates or nicotinic acid) can be 
considered. Statins exert only a modest effect. Treatment 
for isolated low HDL is provided mainly in the patients 
who have manifest CHD or CHD risk equivalents. Current 
recommendations include:
(a)  Identification of patients whose diet is very low in fat. 
A low HDL level in this setting is rarely associated with 
an increased risk for premature CHD;
(b)  Identification and correction of secondary factors, such 
as smoking cessation, weight management, increased 
physical activity, elimination of medications that are 
known to lower HDL levels, and optimal diabetes 
control;
(c)  Use of pharmacologic agents to raise the HDL level in 
otherwise healthy persons. Though no published clini-
cal trials are available yet they demonstrate a benefit. 
Nonetheless, individuals at high risk require further 
assessment for CHD risk, with an evaluation that 
includes a family history, measurements of apoprotein, 
lipoprotein (Lp(a)), and electron beam CT scanning;
(i)  Niacin is the most effective agent currently avail-
able. However, many patients with isolated HA 
do not respond well to niacin.
(ii)  Gemfibrozil and fenofibrate modestly raise the 
HDL level. They are most effective in the setting 
of concomitant hypertriglyceridemia.
(iii)  Alcohol tends to raise some HDL subfractions. 
However, no clinical trial data are available to 
demonstrate any positive role for raising HDL 
levels with alcohol in order to reduce cardiovas-
cular events in patients with CHD.
Therapeutic lifestyle changes
Dietary interventions
Diets that are very low in fat are associated with low 
HDL levels too. However, increasing the fat content of a 
patient’s diet for the purpose of raising HDL is not recom-
mended. Dietary management should follow the NCEP 
guidelines for lowering frequently associated LDL choles-
terol, which is the primary target in lipid management. The 
NCEP has recommended a therapeutic lifestyle-change diet, 
which should be incorporated in the treatment of all patients. 
The following are the recommendations:
(a)  Patients should reduce their intake of saturated fats 
to less than 7% of their total calorie (energy) intake. 
Their cholesterol intake should be reduced to less than 
200 mg/day. Trans fatty acids (the HDL-lowering, 
LDL-raising fats) should be kept to a minimum. 
Polyunsaturated fats should constitute up to 10% of 
total energy intake, and monounsaturated fats, up to 
20% of total energy intake. Total fat intake, therefore, 
should be in the range of 25% to 35% of total energy 
intake.
(b)  Carbohydrates (complex carbohydrates from grains, 
whole grains, fruits, and vegetables) should constitute 
50% to 60% of total energy intake.
(c)  Patients should consume 20 to 30 g/day of fiber.
(d)  The protein content should be approximately 15% of 
the total calorie intake.
(e)  In order to maintain a desirable body weight and 
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consumed must be balanced in terms of energy intake 
and expenditure.
exercise/physical activity
Physical activity, especially regular physical activity, should 
be strongly encouraged in all persons, and particularly in 
those with sedentary habits and low HDL state. According to 
the NCEP guidelines, daily activity and energy expenditure 
should include at least moderate physical activity, with the 
daily energy expending approximating 840 kilo joules or 
greater every day.
Raising HDL: trials (and tribulations)
CeTP inhibitors
One of the pharmacologic approaches that have recently 
undergone clinical evaluation in the randomized trials 
includes attempts at elevation of HDL level through the 
inhibition of the enzyme, CETP. The CETP tends to nega-
tively influence the reverse cholesterol transport pathway by 
mediating the stoichiometric 1:1 exchange of triglycerides 
for esterified cholesterol (cholesteryl ester) between apolipo-
protein B100–containing lipoproteins and HDL molecules. 
As a result, it lowers HDL level and may reduce the amount 
of cholesterol delivered back to the liver via direct RCT. 
Increased CETP activity is pathologic, and tends to acceler-
ate atherogenesis. Therefore, inhibition of CETP activity can 
potentially provide a therapeutic benefit for patients with 
CHD by allowing HDL particles to accumulate and be more 
available for augmenting the RCT process that scavenges 
cholesterol from the tissues. Several approaches to inhibit 
CETP activity and, thus, augment HDL level have been 
examined including use of anti-CETP antibodies, antisense 
oligonucleotides, and a vaccine that induces antibodies for 
the inhibition of CETP action.
Genetic mutations causing CETP deficiency result in 
increased levels of HDL. This information in the recent years 
led to intense interest in the development of CETP inhibi-
tors as therapeutic agents for raising HDL.27,28 Individuals 
homozygous for the CETP mutation that leads to its dysfunc-
tion or deficiency, have been shown to be associated with 
elevations in HDL exceeding 100%, along with more than 
40% decrease in the level of LDL and apo-B as compared 
with familial controls. However, the CETP deficiency is not 
always predictably associated with decreased CHD risk. 
In fact, the studies evaluating the relationship between CETP 
inhibition and extent of atherosclerosis in animal models have 
shown mixed results. While studies with CETP transgenic 
mouse models show inconsistent effects on the progression 
of atherosclerosis, the studies using rabbit models of CETP 
inhibition consistently showed a reduction in atherosclerosis. 
For example, cholesterol-fed rabbits that were treated with 
the CETP inhibitor, torcetrapib, exhibited 4-fold increases in 
HDL associated with a 60% reduction in atherosclerosis.
Studies of the effects of torcetrapib on the vascular system 
(iLLUSTRATe, RADiANCe i and RADiANCe ii trials)
One of the most illustrative studies, the Investigation of Lipid 
Level Management Using Coronary Ultrasound to Assess 
Reduction of Atherosclerosis by CETP Inhibition and HDL 
Elevation (ILLUSTRATE) trial, examined the effects of the 
addition of torcetrapib to atorvastatin therapy on the vascular 
system as assessed by intravascular ultrasound (IVUS).29 A 
total of 1188 patients with known CHD were treated with 
atorvastatin to bring their LDL levels below 100 mg/dL 
before randomization to either atorvastatin monotherapy 
or a combination therapy with atorvastatin and torcetrapib 
(60 mg). At the end of two years of follow-up, patients 
receiving torcetrapib showed a significant 61% increase in 
HDL, and a 20% reduction in LDL compared with those who 
received atorvastatin monotherapy. The primary end point of 
percent atheroma volume did not differ significantly between 
the torcetrapib/atorvastatin group and the atorvastatin group 
(0.12% versus 0.19%, P = 0.72). These patients, however, 
experienced a 4.6 mmHg increase in blood pressure.
Another similar study, the Rating Atherosclerosis 
Disease Change by Imaging with a New CETP Inhibitor 
(RADIANCE 1), evaluated 850 patients with heterozygous 
familial hypercholesterolemia following the addition of 
torcetrapib to baseline atorvastatin therapy and measured 
the change in atherosclerosis by using CIMT as the main 
parameter.30 Patients in the torcetrapib/atorvastatin group 
had significantly higher HDL (82 mg/dL) and lower 
LDL (115 mg/dL) compared with the atorvastatin mono-
therapy group (52 mg/dL and 143 mg/dL, respectively; 
P , 0.001 for both comparisons). However, the increase in 
maximum CIMT was +0.0047 mm/year in the torcetrapib/
atorvastatin group, which was not significantly different 
from the +0.0053 mm/year increase observed in the ator-
vastatin monotherapy group (P = 0.87).30 Again, an aver-
age increase of 2.8 mmHg in systolic blood pressure was 
observed in the torcetrapib/  atorvastatin group compared 
with the   atorvastatin monotherapy group.   Subsequent to 
RADIANCE 1, the   RADIANCE 2 study examined the 
effect of addition of torcetrapib to atorvastatin therapy on 
atherosclerosis progression, as measured by CIMT in patients 
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required to have triglycerides .151 mg/dL and LDL that 
merited statin therapy according to the NCEP ATP guidelines. 
Patients completed a 4-week washout period, in which all 
lipid-lowering therapy was discontinued, before entering an 
atorvastatin run-in phase. The atorvastatin dose was titrated 
to reach target LDL goals of 100 mg/dL, 130 mg/dL, or 
160 mg/dL, according to individual CHD risk based on the 
NCEP guidelines. After completion of the run-in, patients 
(N = 752) continued with atorvastatin therapy (10, 20, 40, 
or 80 mg) and were randomized to receive either torcetrapib 
60 mg or placebo.28 After 24 months of treatment, patients in 
the torcetrapib/atorvastatin group had a 63% increase in HDL 
and a 18% decrease in LDL compared with patients receiv-
ing atorvastatin monotherapy (P , 0.0001). Once again, 
the patients in the torcetrapib/atorvastatin group exhibited 
a 6.6 mmHg elevation in systolic blood pressure compared 
with a 1.5 mmHg elevation in the statin monotherapy group 
(P , 0.0001). Despite significant favorable improvements in 
LDL and HDL in the torcetrapib/atorvastatin group, change 
in maximum CIMT was not significantly different in the 
torcetrapib/atorvastatin group (x = 0.025 mm/year) compared 
with the atorvastatin monotherapy group (x = 0.030 mm/year, 
P = 0.46).31
In summary, the addition of torcetrapib to background 
atorvastatin therapy did not have a significant effect on 
atherosclerosis progression as measured by vascular imag-
ing techniques in the ILLUSTRATE, RADIANCE 1, and 
RADIANCE 2 trials, despite substantial increases in HDL. 
Also, it tended to increase the blood pressure in the treated 
group in all the three studies.
Torcetrapib and clinical outcome trial  
(iLLUMiNATe Study)
The Investigation of Lipid Level Management to Understand 
its Impact in Atherosclerotic Events (ILLUMINATE) Trial 
sought to examine the effects of the addition of torcetrapib 
60 mg daily to baseline atorvastatin therapy in CHD patients 
who were at high risk according to NCEP criteria.32 A total 
of 15,067 participants between 45 and 75 years of age with 
high risk features including prior history of MI, stroke, acute 
coronary syndrome, unstable angina, peripheral vascular 
disease or type 2 diabetes first received atorvastatin titrated at 
2-week intervals to reduce LDL level below 100 mg/dL, and 
subsequently, they were randomized to either   continuation of 
atorvastatin monotherapy or additional torcetrapib 60 mg/day 
on top of the atorvastatin treatment. The primary end point 
was the time to occurrence of a first major CHD event, such 
as death from CHD due to MI, heart failure, or sudden cardiac 
death; non-fatal MI; stroke or unstable angina. At 1-year 
follow-up, the torcetrapib group showed a 72% rise in the 
level of HDL, along with 25% LDL and a 9% TG reduction 
compared with the atorvastatin only group (P , 0.001).32
Unfortunately though, the study was prematurely ter-
minated due to an increased risk of death and major CHD 
events in the torcetrapib/atorvastatin group notwithstanding 
the positive effects on the lipid profile. As described above for 
the ILLUSTRATE and the RADIANCE studies, once again, 
the torcetrapib cohort showed a 5.4 mmHg elevation in blood 
pressure above baseline (P , 0.001). Furthermore, higher 
mortality rate was experienced by the patient population 
in the torcetrapib arm. Overall, there were 93 deaths in the 
torcetrapib/atorvastatin group compared with only 59 deaths 
in the atorvastatin only group (HR = 1.58; P = 0.006). The HR 
for major CHD events was 1.25 in those treated with torce-
trapib plus atorvastatin compared with those on   atorvastatin 
monotherapy alone (P = 0.001).
Ramifications of the results of the torcetrapib trials
If all the four phase III torcetrapib studies are consid-
ered together including the results of the ILLUMINATE, 
  ILLUSTRATE, RADIANCE 1, and RADIANCE 2 studies, 
it becomes clear that the adverse effects heavily outweighed 
any potential benefit emanating from raising the HDL 
levels.29–32 The lack of efficacy in terms of no demonstrable 
improvement in the parameters of atherosclerosis coupled 
with higher incidence of undesirable effects, such as higher 
rates of death, angina, revascularization procedures, and heart 
failure in the ILLUMINATE trial, and an increase in blood 
pressure in all 4 studies suggests a possible relationship to 
the mechanism of action of torcetrapib or CETP inhibitors as 
a class. Although clinical trials with torcetrapib were unsuc-
cessful, it remains to be seen whether other CETP inhibitors 
would have beneficial effects on atherosclerosis without 
the above mentioned adverse effects; some such agents are 
  currently being tested in randomized trials.
New CeTP inhibitors and trials in progress
A trial by Roche Pharmaceuticals (dal-OUTCOMES) using 
an agent similar to torcetrapib in high risk patients with low 
baseline HDL is underway. This drug (dalcetrapib) report-
edly does not raise blood pressure or aldosterone. The study’s 
results should be available within a few years.
intravenous HDL agonists (apo A-1 subtypes) 
Apo A-1 is the main lipoprotein associated with the HDL and 
it is secreted in the liver as well as in the intestine. Similar Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to HDL, apo A-1 levels correlate well with HDL levels. 
Also, apo A-1 corresponds inversely with the extent of ath-
erosclerosis. Physiologically, the apo A-1 molecule acts by 
promoting the cellular cholesterol efflux process. It is also 
a major activator of the enzyme LCAT. As described above, 
apo A-1 is initially secreted as a lipid-void apo A-1 molecule 
(pre-HDL particle) and the lipid component is subsequently 
added to it in the presence of transport protein, such as 
ABCA-1 (lipidation). Studies in animal models have shown 
benefits of directly infusing synthetic apo A-1 models have 
opened a new therapeutic avenue for raising HDL. Apo 
A-1 overexpression in transgenic mice and rabbits has been 
demonstrated to increase the number of circulating HDL 
particles and confer protection from the development of 
diet- or gene-induced atherosclerosis.
Studies in mice and rabbits have used several approaches 
to increase HDL levels, including intravenous administration 
of synthetic HDL, apo A-1, and apo A-1 Milano and have 
demonstrated significant capacity to induce atheromatous 
plaque regression.
While carriers of the regular apo A-1 Milano show severe 
hypoalphalipoproteinemia but no increase in the risk for 
premature CHD, an apo A-1 Milano variant produced by 
substituting cysteine for arginine at position 173 makes the 
molecule quite protective. Such substitution allows more 
effective lipidation and genesis of large HDL particles with 
longer serum half-life. The HDLs derived from patients with 
the apoA-1Milano phenotype have enhanced affinity for ABC 
A-1 and augmented ability for reverse cholesterol transport 
process. Apo A-1 Milano also exhibits greater affinity for 
ABCA-1 and more pronounced capacity to antagonize lipid 
oxidation and thrombosis as compared with native apo A-1. 
It is, therefore, reasonable to assess the therapeutic utility 
of direct intravenous infusion of the apo A-1 variants in the 
setting of established CHD.
eTC 216 study (intravenous apo A-1 Milano/phospholipid 
complex infusion)
The effect of once-weekly intravenous infusion was stud-
ied by Nissen et al in 123 patients with established CHD 
using recombinant apo A-1 Milano/ 1-palmitoyl-2-oleoyl 
phosphatidylcholine complex (ETC 216). Efficacy on the 
atheroma burden was measured by IVUS both at baseline 
and at 5 weeks. A significant regression of coronary athero-
sclerosis was demonstrated as indicated by change in per-
cent atheroma volume -4.2% versus -0.8% [P , 0.001] in 
patients treated with ETC 216 and placebo respectively. The 
mean change in the total atheroma volume was -14.1 mm3 
versus -2.9 mm3 [P , 0.001] in patients assigned to ETC 
216 and placebo respectively.29
eRASe study
In the Atherosclerosis Safety and Efficacy (ERASE study), 
183 patients were randomized to receive placebo or one 
of the two dosages, 40 mg/kg or 80 mg/kg, of CSL-111 
intravenously for a 4-week period. The molecule CSL-111-
was produced as a reconstituted HDL particle consisting 
of apo A-1 from human plasma combined with soybean 
phosphatidylcholine, which chemically and biologically 
resembles native HDL. Plaque characterization by IVUS and 
quantitative coronary angiography was performed at baseline 
and at 4 weeks that showed significant improvement in the 
plaque characteristics in the treated groups as compared with 
  placebo. However, no significant differences were found in 
the atheroma volume. Also, the higher dosage of CSL-3 
treatment (80 mg/kg) had to be discontinued early because 
of the development of liver function abnormalities.
Thus, although infusible HDL agonists seem to provide 
benefit in the short term as shown by plaque regression 
through IVUS assessment, much more work must be done 
to better characterize the potential efficacy of these therapies 
in both the near and long term to see if clinical outcome is 
influenced in the patients at high risk. In addition, safety 
concerns, such as anaphylactic reactions, liver dysfunc-
tion, and cost implications will quite likely impact further 
testing and usage. One intriguing possibility may be that 
such an approach to HDL modulation by treating it in acute 
situations may offer means by which to stabilize vulnerable 
atheromatous plaques and decrease their propensity to rupture 
and cause acute coronary events.
Niacin and HDL
Studies with niacin
Niacin, also called nicotinic acid, is one of the water-soluble 
B vitamins. It favorably modifies most of the lipid subfrac-
tions, including raising the HDL levels. Niacin acts by 
binding to the surface of the adipocytes through a receptor 
labeled HM74 (or gp109A). This binding inhibits hormone-
sensitive lipase that results in decreased mobilization of 
fatty acids into the portal circulation. Additionally, niacin 
decreases the formation of triglycerides by inhibiting the 
enzyme, acyl-coenzyme A: diglycerol acyltransferase 2 
(DGAT2) that esterifies mono- and diglycerides to form 
triglycerides. Niacin also increases apo-B100 catabolism 
causing reduced VLDL and triglyceride secretion by the 
liver. Niacin raises serum HDL levels by decreasing HDL Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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catabolism in the liver by down-regulating the expression 
of the F1 moiety of F1F0 ATP synthetase, a holoparticle 
HDL receptor. Another mechanism by which niacin raises 
HDL-C level may include the reduced enrichment of HDL 
with triglyceride and its subsequent catabolism by hepatic 
lipase enzyme.
Niacin is currently the most effective pharmacotherapeutic 
agent approved and available for raising HDL-C.33 It has 
an established safety profile and has been used for over 50 
years. According to ADA and NCEP, niacin can safely be 
used even in patients with diabetes. Lately, it has been tested 
and found efficacious in combination therapy with statins to 
simultaneously reduce LDL and raise HDL.34 The coronary 
drug project (CDP), a placebo-controlled trial conducted 3 
decades ago, randomized 6341 men with prior history of 
MI, to evaluate the effectiveness of 5 different lipid-altering 
agents that included clofibrate, dextrothyroxine, low- and 
high-dose estrogen and niacin. Due to undesirable side effects 
estrogen and dextrothyroxine groups were prematurely 
stopped, while the niacin and clofibrate groups completed 
the 6.2-year study. Even though the total mortality was not 
significantly different in the niacin group compared with the 
placebo group (24.4% and 25.4% respectively), significant 
reduction was seen in the niacin cohort in the combined 
outcome of CHD death and MI (15%, P , 0.05), non-fatal 
MI (26%, P , 0.05), cerebro-vascular events (24%, P 
, 0.05), and need for cardiac surgery (47%, P , 0.05).35 
Nine years following the termination of the CDP trial, a 
15-year follow-up was performed and a remarkable finding 
was made. Reviewers now found that, at 15 years, mortality 
reduction had become significant in the niacin group. Com-
pared with the placebo group, the niacin group experienced 
an 11% reduction in total mortality and 12% reduction in 
CHD mortality (P = 0.0004 and P , 0.05, respectively.36 
These findings suggest that treatment with niacin increased 
survival and the benefit was maintained even after stopping 
the therapy.
improving niacin compliance
Compliance is a significant issue because of the significant 
frequency with which patients experience flushing as a side 
effect and opt to discontinue niacin. It has been often noted 
that when physicians sit down with patients and discuss the 
benefits and nuances of niacin, patient compliance goes up. 
In fact, the significance of physician support in increasing 
compliance to niacin was evaluated in the Impact of Medical 
Subspecialty on Patient Compliance to Treatment (IMPACT) 
study.37 The researchers concluded that long-term adherence 
to niacin therapy is greatly dependent on patient education 
and awareness. The physicians and supporting health team 
members should discuss with the patients directly about the 
side effect of flushing and the high possibility of develop-
ment of tolerance over time if the treatment was continued 
without interruption, which can prevent tolerance from 
developing.
Several formulations of extended release niacin that seem 
to have much less problem of flushing as well as higher rates 
of tolerance with continued use have been developed and 
studied over the past decade. In a study, niacin ER was in 
doses of up to 3 g daily was evaluated in 517 patients who 
were followed for about 10 months. Over the course of the 
study, the number of patients who reported the episodes of 
flushing progressively declined by 90%. Most patients expe-
rienced 1 mild flush per month on an average.38 Strategies 
to reduce flushing include several simple measures. Such 
measures may include (a) use of niacin ER once daily at 
bedtime, (b) taking niacin with aspirin or another nonsteroidal 
anti-inflammatory agent taken approximately 30 minutes 
prior, (c) gradual increase in the dose, (d) taking niacin 
with a low-fat, high-fiber snack, and (e) avoiding triggers 
such as heat or ingestion of alcohol or spicy foods.39 A new 
formulation of niacin ER that is now available has shown 
a significant 42% to 43% decrease in median severity and 
duration of flushing (P , 0.0001) as compared with the old 
formulation.40 Furthermore, Cefali et al used the niacin ER 
(2000 mg) and tested the effectiveness of 650 mg aspirin 
on flushing when the aspirin was given 30 minutes prior 
to niacin therapy, concomitant with niacin therapy, or not 
at all. Both, pre- and concomitant treatments with aspirin, 
exhibited 42% reduction in median severity of flushing as 
compared with the new formulation of niacin ER without 
aspirin (P , 0.001).41
Cordaptive (extended-release niacin and PGD1  
receptor antagonist)
Niacin raises the HDL by 15% to 30%. Despite its ability to 
significantly increase the HDL levels, the use of niacin in the 
treatment of low HDL has been limited due to its side-effect 
of flushing. The flushing is caused by cutaneous vasodilation 
leading to warmth and itching. Such vasodilatation is mediated 
by activation of the formation of prostaglandin D2 (15-deoxy-
D12,14-prostaglandin J2), which binds to the prostaglandin D2 
receptor 1 (PGD1 receptor) in the skin. Therapeutic agents that 
can block the PGD1 receptor may have the potential to reduce 
the prostaglandin D2 production and subsequent cutaneous 
flushing. Laropiprant is one such agent under investigation.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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A novel therapeutic agent, Cordaptive, previously known 
as MK-0524A, is a combination of extended-release niacin 
and a PGD1 receptor blocker (laropiprant), which functions 
to prevent activation of vasodilatation by prostaglandin D2.42 
It has been shown in limited clinical studies to reduce symp-
toms of flushing. Cordaptive is already approved for use in 
the European Union but not in the US. Cordaptive is now 
being studied in ACHIEVE and HPS2-THRIVE (the Treat-
ment of HDL to Reduce the Incidence of Vascular Events) 
studies. These trial data may lead to its approval in the US if 
the benefit/risk ratio comes out to be favorable.
A word of caution about Cordaptive or laropiprant is, 
however, in order. One of the metabolites of prostaglandin D2 
is a potent endogenous PPAR-γ agonist that promotes expres-
sion of ABCA-1 and increases transfer of cholesterol from 
macrophages to HDL. Cordaptive, by reducing prostaglandin 
D2 production, thus, may potentially cause an undesirable side 
effect of decreasing the ability of prostaglandin D2 to stimu-
late expression of ABCA-1 on the surface of macrophages.
Aggressive statin monotherapy for raising HDL
There are substantial data available in the literature from 
multiple randomized clinical trials proving beyond doubt 
that statins significantly reduce LDL and improve clinical 
outcomes. HDL is usually only modestly raised by using 
the statins in higher doses as part of aggressive statin mono-
therapy. Several trials incorporating angiography, IVUS 
or measurement of CIMT have demonstrated that treat-
ment with aggressive statin monotherapy that aggressively 
lowers LDL and modestly raises HDL (by 10% to 15%) 
significantly reduces the progression of atherosclerosis. 
The Arterial Biology for the Investigation of the Treatment 
Effects of Reducing Cholesterol (ARBITER) study explored 
whether bringing LDL to much below 100 mg/dL would 
decrease atherosclerosis progression as measured by CIMT 
in 161 patients treated for 12 months. The LDL decreased to 
a mean of 76 mg/dL with atorvastatin 80 mg in the aggressive 
therapy group and showed significant concomitant CIMT 
regression (-0.034 mm) as compared with pravastatin group 
(+0.025 mm, P = 0.03).43
The Measuring Effects on Intima-Media Thickness: 
an Evaluation of Rosuvastatin (METEOR) study assessed 
the effect of very high-intensity statin therapy on CIMT 
over 2 years. The patients in the rosuvastatin group expe-
rienced a 49% reduction in LDL (mean, 78 mg/dL) along 
with significantly slowed progression of atherosclerosis as 
  measured by CIMT (-0.0014 mm/year) compared with pla-
cebo (+0.0131 mm/year, P , 0.001).44 These studies showed 
slowed progression but did not show significant atheroma 
regression.
Regression of atherosclerosis was demonstrated in 
A Study to Evaluate the Effect of Rosuvastatin on Intra-
vascular Ultrasound-Derived Coronary Atheroma Burden 
(ASTEROID) examined the effects of high-dose rosuvastatin 
on progression of coronary atherosclerosis. The mean LDL 
was reduced by 53% to 60.8 mg/dL (P , 0.00) and the mean 
HDL was increased by 15% to 49.0 mg/dL (P , 0.001).45 
The primary efficacy parameter of mean percent atheroma 
volume (PAV) was reduced from 39.6% to 38.6%, (-0.98%, 
P , 0.001). For this measure, the mean percent atheroma 
volume, 63.6% of patients experienced regression. If total 
atheroma volume was used as the parameter and applied to 
only the subsegment with greatest disease severity, 78.1% 
of patients exhibited disease regression. When quantitative 
coronary angiography (QCA) was used for the same patients, 
the mean percent diameter stenosis was reduced from 37.3% 
to 36.0% after 24 months of rosuvastatin 40 mg therapy 
(P , 0.001).46
Combination therapies for raising HDL
HDL-Atherosclerosis Treatment Study (HATS)
In HATS, simvastatin and niacin combination therapy 
was compared with placebo in CHD patients with low 
HDL (#35 mg/dL in men or #40 mg/dL in women) and 
LDL-C levels #145 mg/dL and followed them for 3 years 
in a double-blind fashion.47 Patients in combination therapy 
group experienced a 42% reduction in LDL, a 36% reduc-
tion in TG, and a 26% elevation of HDL (P , 0.001) over 
their baseline values. While patients who received placebo 
showed progression of the most severe coronary stenosis 
(+3.9%), the patients who received the combination therapy 
exhibited regression (-0.4%, P , 0.001). Clinical outcome 
was significantly improved as well in the form of a strik-
ing 90% reduction in the CHD events in patients receiving 
simvastatin and niacin combination therapy compared with 
patients who received placebo (P = 0.03).
Familial Atherosclerosis Treatment Study (FATS)
FATS examined the efficacy of combination therapy using 
either lovastatin and colestipol, niacin and colestipol, or 
placebo in addition to dietary counseling as measured by 
QCA in men with CHD and a family history of vascular 
disease. In patients treated with combination therapies, such 
as   lovastatin and colestipol and niacin and colestipol, the 
LDL was reduced by 46% and 32%, respectively (P , 0.001 
versus baseline) and HDL was increased by 15% and 43%, Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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respectively (P , 0.01 and P , 0.001 versus baseline). In 
contrast, the placebo group merely showed 7% decline in 
the LDL and 5% rise in the HDL. Among those patients 
receiving placebo, 46% showed lesion progression and 11% 
showed lesion regression in at least 1 of 9 proximal coronary 
segments evaluated.48 In comparison, patients receiving 
lovastatin and colestipol or niacin and colestipol had less 
frequent lesion progression (21% and 25%, respectively) 
and significantly more frequent lesion regression (lovastatin 
and colestipol, 32%; niacin and colestipol, 39%; P , 0.005 
versus placebo). Clinical events, such as death, MI, or revas-
cularization were similarly influenced. While 19.2% patients 
in the placebo group experienced a CHD event, only 6.5% of 
the patients did so in the lovastatin and colestipol group and 
4.2% of patients in the niacin and colestipol group.
In a Follow-up study of FATS trial, 75 patients on triple 
combination therapy with niacin, colestipol, and lovastatin 
were followed further. At 10 years, approximately19.8% 
of the patients in the control group died as compared with 
only 1.3% of the patients in the triple therapy group (relative 
risk reduction = 93%, P , 0.001). In addition, 18.8% of the 
control group experienced a composite endpoint of death or 
MI compared with 5.3% of the patients in the triple therapy 
group (relative risk reduction = 67%, P , 0.02).49
Arterial Biology for the investigation of the Treatment 
effects of Reducing Cholesterol trials: ARBiTeR-2 and 
ARBiTeR-3 (niacin eR and statin).
Combination therapy with niacin formulations and statin 
was evaluated in the ARBITER-2 and ARBITER-3 trials. 
In the ARBITER-2, a year-long treatment with a com-
bination regimen involving extended-release niacin and 
atorvastatin was given to patients with known CHD and 
low HDL (defined as ,45 mg/dL) in a double-blind, ran-
domized manner with placebo control.50 The primary end 
point of the study was the change in CIMT from baseline 
after 12 months of treatment. While there were no sig-
nificant changes seen in the LDL levels; the HDL levels 
significantly increased by 21% and TG levels significantly 
declined by 13% (P = 0.003 and P = 0.03 respectively). The 
CIMT increased significantly by +0.044 mm in the statin 
monotherapy (control) group (P , 0.001 versus baseline). 
In contrast the increase was much less, ie, +0.014 mm, 
and it remained non-significant in the combination therapy 
group (P = 0.23 versus baseline).
The ARBITER-3 trial was an extension study of 
  ARBITER 2 that permitted patients in the placebo (statin 
monotherapy) group to cross over to niacin ER and statin 
combination regimen. These crossed over patients exhibited 
significant 12% drop in LDL (P = 0.012), 33% drop in 
TG (P = 0.001) and 24% rise in HDL (P , 0.001) after 2 
years of niacin ER therapy. Furthermore, at 1- and 2-year 
points following the start of combination therapy, regres-
sion in atherosclerosis was noted by CIMT (-0.027 mm 
and –0.041 mm, respectively; P , 0.001 versus statin 
monotherapy).51 High-risk patients with diabetes or the 
metabolic syndrome who were randomized to combination 
therapy, experienced somewhat greater regression of CIMT 
(-0.046 mm, P , 0.001). More interestingly, a statisti-
cally significant inverse correlation between the increase 
in HDL and the regression of CIMT (P = 0.002) was noted 
  suggesting that raising HDL with niacin ER over and above 
the statin treatment may account for the beneficial effect of 
  atherosclerosis regression encountered.
Combination therapy and CHD risk reduction: summary
A recent meta-analysis compared statin monotherapy trials 
and combination lipid-modifying therapy trials using clinical 
event relative risk reduction and the number needed to treat 
(NNT to prevent 1 CHD event.52 These studies had diverse 
patient populations, numbers of subjects, and treatment 
durations, which merits consideration when interpreting 
the results.
The six clinical end point LDL-lowering trials 
included the Scandinavian Simvastatin Survival Study 
(4S), Long-Term Intervention with Pravastatin in Isch-
emic Disease (LIPID), Cholesterol And Recurrent Events 
Trial (CARE), West of Scotland Coronary Prevention 
Study Group (WOSCOPS), Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AF/TexCAPS), and 
Collaborative Atorvastatin Diabetes Study (CARDS). 
These achieved an average clinical event relative risk 
reduction of 27.2% and an average NNT per year of 8.5. 
In addition, the three recent, intensive LDL-lowering 
clinical end point trials (IDEAL, TNT, and PROVE IT) 
achieved an average clinical event relative risk reduction 
of 16.0% and an average NNT per year of 19.1. Further-
more, five angiographic LDL- lowering trials that include 
Monitored Atherosclerosis Regression Study (MARS), 
Multicentre Anti-Atheroma Study (MAAS), Regression 
Growth Evaluation Statin Study (REGRESS), Pravastatin 
Limitation of Atherosclerosis in the Coronary Arter-
ies (PLAC-I), and Canadian Coronary Atherosclerosis 
Intervention Trial (CCAIT), achieved an average clinical 
event relative risk reduction of 29.6% and an average 
NNT per year of 28.7.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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In contrast, clinical trials that tested combination therapies 
for simultaneously lowering LDL and raising HDL, such 
as FATS, FATS- long follow-up, Cholesterol Lowering 
  Atherosclerosis Study (CLAS), CLAS- 2-year follow-up, 
HATS, and Stanford Coronary Risk Intervention Project 
(SCRIP), exhibited much higher efficiency. They achieved an 
average clinical event relative risk reduction of 71.6% and an 
average NNT per year of only 3.4. These data suggest enhanced 
efficiency for reducing clinical events using   LDL-lowering plus 
HDL-raising therapy versus LDL-lowering therapy alone.
In 2007, a National Lipid Association (NLA) task force 
examined the safety of niacin therapy and concluded that 
2 decades of clinical evidence does not show an adverse 
augmentation of myopathy by niacin whether used alone or in 
combination with statins. Therefore, the addition of niacin to 
statin monotherapy appears to be a safe method for improving 
multiple atherogenic lipid abnormalities including raising the 
HDL in high risk CHD patients. Niacin should, however, 
be prescribed to patients as such or in the extended-release 
form. Some of the niacin formulations found in health food 
stores has been shown to cause significant hepato-toxicity 
which is not seen with the prescription forms of niacin ER.53 
In fact, the use of such unregulated niacin preparations has 
been discouraged by the AHA.
Future HDL-raising therapies
PPAR-γ agonists
Some of the currently available dyslipidemic agents that 
include the fibric acid derivatives, such as gemfibrozil, feno-
fibrate, and bezafibrate, are PPAR-γ agonists. These agents 
have not been that potent, however. Some of the newer more 
potent agents are currently undergoing trials that hold sig-
nificant promise for use as future HDL-raising agents. The 
PPAR-γ is one of the several PPAR isoforms that include 
PPAR-γ, PPAR-β/σ, and PPAR-γ. The PPARs are nuclear 
transcription factors. PPAR isoforms have varying proper-
ties that depend on their target genes and tissue distribution. 
For example, while the PPAR-γ regulates genes involved in 
fatty acid uptake and storage, inflammation, and lipoprotein 
metabolism, the PPAR-γ regulates genes involved in glucose 
and fatty acid metabolism, inflammation, and macrophage 
lipid homeostasis.54
The activation of PPAR-γ causes rise in the serum HDL 
level by several mechanisms that include stimulation of 
hepatic apo A-1 expression, promotion of TG catabolism 
by activating lipoprotein lipase, decreasing the enrichment 
of HDL with TG and eventually reducing the lipolysis and 
  catabolism of HDL by hepatic lipase.55 Furthermore, the 
hepatic apo A-1 and apo A-2 expression is increased on 
activation of PPAR-γ. The activation of the PPAR-γ also aug-
ments the cholesterol efflux, accelerates RCT and raises the 
HDL level. The PPAR-γ agonists act to affect atheros  clerosis 
by several additional mechanisms including improving 
vascular wall reactivity, reducing expression of endothelial 
adhesion molecules, and decreasing levels of inflammatory 
cytokines such as tumor necrosis factor-α (TNF-α), inter-
leukin (IL)-I, and IL-6.
Clinically the fibric acid derivatives act to decrease 
plasma TGs and VLDL and increase HDL. They are, 
therefore, recognized as first-line agents in the treatment of 
primary hypertriglyceridemia, combined hyperlipidemia, 
and secondary lipid abnormalities including mixed dyslipi-
demias. While fibrates are PPAR-γ agonists, they demon-
strated only weak agonist activity. They have to be used in 
high doses, such as 145 to 1200 mg daily to achieve desired 
lipid-lowering effects.
Currently, somewhat more potent and subtype-selective 
PPAR-γ agonists are under development.56 They include 
GFT505, a selective PPAR-γ modulator that is 100-times 
more potent than fenofibrate. There are several other new 
selective PPAR-γ agonists in the pipeline that may prove 
beneficial in improved regulation of lipid metabolism as well 
as augmentation of HDL levels.
Liver X-receptor-α agonists
LXRs are also nuclear transcription factors that are 
involved in the regulation of lipid metabolism and regula-
tion of inflammation. They have the potential of raising 
HDL levels because they up-regulate the ABCA-1 and 
ABCG-1 receptors in the macrophages that promote 
RCT.57 Thiazolidinediones are molecules that activate 
LXR-α and increase expression of ABCA-1 and ABCG-1 
but they are not therapeutically usable as such. Synthetic 
LXR agonists that are currently under development cause 
regression of atherosclerosis and enhance macrophage 
cholesterol efflux and RCT process in the animal models. 
They were shown to inhibit the progression of athero-
sclerosis in LDL receptor knockout and apo-E knockout 
mice., LXR agonists also inhibit lipopolysaccharide-in-
duced expression of proinflammatory genes and decrease 
  inflammation in mouse models.
There is a potential negative side to this approach. The 
therapeutic benefit of LXR agonists could be diminished 
because of LXR-mediated increases in plasma and hepatic 
triglycerides resulting from induction of lipogenic genes, 
including sterol response element binding protein-1c Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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(SREBP-1c) and the enzyme, fatty acid synthase. This can 
lead to increased risk of developing hepatic steatosis.
Several of the new LXR agonists are currently undergo-
ing evaluation. One such synthetic agent, GW3965, was 
found to increase the rate of RCT in vivo without inducing 
hepatic steatosis. Continued interest in LXR agonism as a 
potential therapeutic approach may one day lead to more 
selective LXR modulators with lesser tendency for hepatic 
steatosis.58
D-4F and other apo-A like agents
The apoprotein subunit of the apoipoprotein contains 
α-helices that are n-amphipathic and help stabilize the 
structure and size of lipoproteins. These helical regions in 
the apolipoprotein of the HDL, apo A-1, similarly allows 
HDL to dock with the cell surface receptors ABCA-1 and 
SR-BI. The apoprotein agonists may have the potential to be 
used as therapeutic agents for augmenting HDL. However, 
one must note that the apoprotein agonists are amphipathic 
α-helices that do not necessarily raise the serum levels of 
HDL in quantity. Instead, such agents augment the functional 
quality or overall effectiveness of HDL-C.
One of the apo A-I agonists, D-4F, is a molecule that 
is resistant to hydrolysis by gastric peptidases because it is 
composed of D-amino acids with 4 phenyl-alanine residues 
in its amino acid sequence, and can be taken orally. D-4F has 
been shown to enhance the antioxidant and anti-inflammatory 
properties of HDL, and accelerate the RCT process.59 The 
antiatherogenic effect of D-4F has been demonstrated in 
hyperlipidemic mice and in apolipoprotein E-null mice. 
When given orally to mice and monkeys, D-4F leads to 
greater production of pre-β HDL, and improved HDL-
  mediated cholesterol efflux from macrophages to some 
extent. More importantly, D-4F helps convert proinflamma-
tory HDL to anti-inflammatory HDL.60
In a study, D-4F, when orally administered to the LDL 
receptor-null mice that were fed Western diet and apoE-null 
mice that were fed chow diet, demonstrated decrease in the 
atherosclerotic lesions by 79% and 75%, respectively, with-
out significantly altering the plasma lipid levels.61 Thus, the 
studies using D-4F are intriguing; however, we have a long 
way to go before its optimal use, systemic effects and safety 
profile are fully worked out. If results come out favorable, 
the D-4F may become quite a cost-effective agent for use 
as an apo A-1 agonist for patients with low HDL levels or 
dysfunctional RCT. A number of additional apo A-1 agonist 
peptides are also in development at the present time and hold 
promise for HDL therapy.
Farnesoid X receptor (FXR) antagonists
The farnesoid X receptor (FXR) molecule belongs to the 
nuclear receptor family. FXR participates in the regulation 
of bile acid synthesis, conjugation, and transport.62 It also 
enhances the expression of one of the enzymes, phospholipid 
transfer protein, involved in HDL formation, and lowers TG 
levels by inducing PPAR-α that promotes clearance. One of 
the most important functions of FXR activation is to inhibit 
cholesterol 7-alpha-hydroxylase, the rate-limiting enzyme in 
bile acid biosynthesis. FXR is expressed in a wide variety of 
tissues, including the heart, kidney, thymus, and spleen, and 
vasculature. The role of FXR in HDL metabolism is unclear, 
however, the apoA-I and hepatic lipase expression are both 
inhibited by activated FXR. Thus, antagonizing FXR function 
to favorably influence HDL metabolism and RCT is intrigu-
ing. Studies on the use of guggolipid as an antagonist of FXR 
have not demonstrated consistent results in raising HDL.63 
Therefore, much more research is needed to establish what 
role FXR plays in the HDL metabolism and what if any role 
FXR modulators have in CHD prevention in future.
Conclusions
Despite significant reductions in CHD events with statin 
therapy, significant proportion of residual events still occur, 
and they are unacceptable. HDL is a significant, independent 
risk factor that has been suggested as the next therapeutic 
target for reducing residual CHD risk. There is an inverse 
relationship between HDL and CHD risk that may be attrib-
uted to the role of HDL in promoting reverse cholesterol 
transport process and imparting additional antiatherogenic 
actions. In recognition of the significant risk associated with 
low HDL levels, national guidelines now support raising HDL 
to reduce CHD risk once LDL goals are met. Currently, the 
recommended therapies for raising HDL include lifestyle 
modification, and use of niacin, fibrates or combination 
therapeutic agents. Although statin therapy has an estab-
lished efficacy in increasing HDL levels, only minor overall 
increases in HDL have been demonstrated. Multiple new 
agents that affect HDL metabolism are undergoing trials, 
and the outcomes of these trials may lead to better therapies 
in future. Thus, it is likely that the modulation of HDL levels 
or its properties will significantly impact future approaches 
to the management of cardiovascular disease in both the 
primary and secondary prevention settings.
These promising therapies include therapeutic adjustment 
of enzymes that remodel HDL and facilitate transfer reactions 
among lipoproteins, such as CETP, phospholipid transfer 
protein, endothelial lipase, lipoprotein lipase, and hepatic Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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lipase. In addition, the Infusible apoproteins and HDL, 
apo A-1 agonists, nuclear transcription factor agonists, and 
macrophage-surface ABC transporters will also find a role 
in HDL modulation. Certainly, well-designed clinical studies 
and large clinical trials will be needed to demonstrate both 
safety and efficacy given the difficulties and lessons learned 
from the torcetrapib trials rather than mere demonstration of 
atherosclerosis modification through IVUS, or CIMT.
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